Article

In silico Antibody Mutagenesis for Optimizing its Binding to the Spike Protein of SARS-CoV-2

2020-09-18

Abstract excerpt

Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic and there are currently no FDA approved medicines for treatment or prevention. Inspired by promising outcomes for convalescent plasma treatment, developing antibody drugs (biologics) to block SARS-CoV-2 infection has been the focus of drug discovery, along with tremendous efforts in repurposing small-molecule drugs. In the last several months, exper...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2120242c-ce49-5711-b151-3695ef6e55c6
DOI: 10.26434/chemrxiv.12967832.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

In silico Antibody Mutagenesis for Optimizing its Binding to the Spike Protein of SARS-CoV-2DOI 10.26434/chemrxiv.12967832.v1Read

In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.Semantic proximity Read

Elucidating important structural features for the binding affinity of spike ‐ SARS‐CoV ‐2 neutralizing antibody complexesSemantic proximity Read

A High-Resolution Approach to Mapping Spike Protein Evolution for Advancing Antibody Therapy DesignSemantic proximity Read

Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapiesSemantic proximity Read

Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody.Semantic proximity Read

Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variantsSemantic proximity Read

Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody InteractionsSemantic proximity Read

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike proteinSemantic proximity Read

Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.Semantic proximity Read

Predicting spike protein NTD mutations of SARS-CoV-2 causing immune evasion by molecular dynamics simulations.Semantic proximity Read

An <i>in vitro</i> experimental pipeline to characterize the binding specificity of SARS-CoV-2 neutralizing antibodiesSemantic proximity Read

Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variantsSemantic proximity Read